# Ankylosing Spondylitis Treatment Market

> Ankylosing Spondylitis Treatment Market Research Report By Treatment Type (Non-Steroidal Anti-Inflammatory Drugs, Tumor Necrosis Factor Inhibitors, Interleukin Inhibitors, Analgesics, Disease Modifying Anti-Rheumatic Drugs), By Route of Administration (Oral, Injectable, Topical), By Patient Type (Adults, Pediatric), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2026 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.9%
- **2025:** USD 6.75 Billion
- **2035:** USD 13.13 Billion
- **Key Players:** Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, UCB S.A., Pfizer Inc., Celltrion Inc., Sandoz Group AG

**Report ID:** MRFR/HC/10650-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** November 04, 2026

**URL:** https://www.marketresearchfuture.com/reports/ankylosing-spondylitis-treatment-market-12171

---

## Market Summary

## Ankylosing Spondylitis Treatment Market Summary

The Ankylosing Spondylitis Treatment Market was valued at USD 6.75 billion in 2025 and is projected to reach USD 7.20 billion in 2026, advancing to USD 13.13 billion by 2035 at a CAGR of 6.9% over 2026–2035. Two catalysts anchor this trajectory. The U.S. Food and Drug Administration cleared bimekizumab for both radiographic and non-radiographic axial disease in September 2024, adding a dual IL-17A/IL-17F mechanism to the treatment ladder [5]. In parallel, the Medicare Part D redesign capped annual out-of-pocket drug spending at USD 2,000 from 2025, removing a major affordability barrier for older patients on self-injected biologics [14].

Therapy in the Ankylosing Spondylitis Treatment Market is shifting away from a TNF-only paradigm. For two decades, adalimumab, etanercept, and infliximab defined second-line care after NSAIDs; today, IL-17 blockers and oral JAK inhibitors compete for first biologic and post-TNF positions, while [biosimilars](https://www.marketresearchfuture.com/reports/biosimilars-market-1329) reset the price of the incumbent class. Upadacitinib delivered an ASAS40 response of 45% versus 18% for placebo in biologic-experienced patients, giving prescribers a credible tablet option [9]. More than 60 biosimilars now hold FDA approval, with adalimumab alone accounting for ten.

North America leads the Ankylosing Spondylitis Treatment Market with a 41.8% share in 2025, supported by high biologic penetration and broad commercial coverage. Asia Pacific is the fastest-growing region at an 8.6% CAGR as reimbursement lists widen in China and diagnosis rates rise in India. Europe ranks second, driven by tender-based biosimilar uptake that frees budget for newer mechanisms. Over the next decade, revenue will increasingly follow mechanism differentiation and access economics rather than first-mover status.

## Key Report Takeaways

### • By Drug Class

- TNF Inhibitors held a 50.4% share of the Ankylosing Spondylitis Treatment Market in 2025, sustained by long clinical familiarity and wide formulary placement
- NSAIDs are expanding at an 8.3% CAGR, the fastest of any drug class, as continuous COX-2 therapy gains standing as a structure-modifying option
- IL-17 Inhibitors generated USD 1.58 billion in 2025 revenue on the back of secukinumab, ixekizumab, and bimekizumab

### • By Route of Administration

- Subcutaneous delivery accounted for 55.4% of 2025 revenue, reflecting self-administration convenience and autoinjector adoption
- Oral therapies are the fastest-growing route in the Ankylosing Spondylitis Treatment Market at an 8.5% CAGR, propelled by JAK inhibitor uptake

### • By Distribution Channel

- Hospital Pharmacies captured a 46.9% share, anchored by biologic initiation and infusion services
- Online Pharmacies are growing at an 8.0% CAGR through home delivery, cold-chain logistics, and digital adherence support

### • By Region

- North America commanded a 41.8% share in 2025 on the strength of U.S. biologic utilisation
- Asia Pacific is projected to grow at an 8.6% CAGR, the highest regional rate
- Europe generated USD 1.86 billion in 2025, shaped by national biosimilar tenders

## Market Size and Forecast (2021–2035)

Estimates for the Ankylosing Spondylitis Treatment Market combine company-reported product revenue for the leading branded and biosimilar agents, prescription-volume data across hospital, retail, and online channels, published prevalence studies, and structured interviews with rheumatologists, pharmacists, and payers. Historical values were reconciled against annual reports and regulatory filings, while forecast values reflect patent expiries, label expansions, and pricing policy timelines.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| IL-17 and dual IL-17A/F label expansion | +1.4% | North America, Europe | Medium-term (2–4 yr) | [5][6][10] |
| Oral JAK inhibitor adoption | +1.1% | North America, Japan, Europe | Medium-term (2–4 yr) | [9] |
| Asia Pacific reimbursement expansion | +0.9% | China, South Korea, India | Long-term (≥4 yr) | [20] |
| Guideline-backed NSAID repositioning | +0.8% | Global | Long-term (≥4 yr) | [2][3][11] |
| Medicare Part D out-of-pocket cap | +0.7% | United States | Short-term (≤2 yr) | [14] |
| Specialty and online home delivery | +0.5% | North America, Europe | Medium-term (2–4 yr) | [17] |

### IL-17 and Dual IL-17A/F Label Expansion

IL-17 blockade is now a first-biologic candidate rather than a post-TNF fallback. Bimekizumab produced an ASAS40 response of 44.8% at week 16 in the BE MOBILE 2 study compared to 22.5% for a placebo in radiographic disease [10]. In October 2023, Novartis introduced an intravenous Cosentyx formulation, opening infusion-center channels for a previously injection-only medication [6]. Deeper rheumatic field forces are funded by Cosentyx's commercial scale, which generated over USD 6 billion in revenue across all indications in 2024 [7].

### Oral JAK Inhibitor Adoption

Patients who are resistant to injections and payers looking for easier logistics will find tablets appealing. Upadacitinib currently has U.S. labeling for both radiographic and non-radiographic axial illness after SELECT-AXIS 2 shown that it achieved ASAS40 in 45% of biologic-experienced patients vs to 18% on placebo [9]. In December 2021, tofacitinib obtained its AS indication [24]. In patients under 65 who do not have cardiovascular risk, rheumatologists are increasingly prescribing JAK inhibitors following one TNF failure.

### Asia Pacific Reimbursement Expansion

China's National Healthcare Security Administration has added several IL-17 and TNF biologics to the National Reimbursement Drug List through annual negotiation rounds, often with price cuts exceeding 50% in exchange for volume [20]. Lower patient co-payments are converting a large, previously untreated population into biologic users. Prevalence in Asia averages 16.7 per 10,000 adults [23], which translates into millions of potential patients across China and India alone.

### Guideline-Backed NSAID Repositioning

Both the 2019 ACR/SAA/SPARTAN recommendations and the 2022 ASAS-EULAR update keep NSAIDs as first-line therapy for active axial disease [2][3]. A cohort analysis found that continuous NSAID use reduced radiographic progression compared with on-demand dosing, with a mean mSASSS change of 0.4 versus 1.5 units over two years [11]. That evidence supports longer treatment durations for selective COX-2 inhibitors such as celecoxib and etoricoxib, lifting volumes even at generic prices.

### Medicare Part D Out-of-Pocket Cap

The Inflation Reduction Act capped annual Part D out-of-pocket costs at USD 2,000 from January 2025 and introduced a payment-smoothing option that spreads costs across the year [14]. Before the cap, beneficiaries on a self-injected biologic could face coinsurance well above USD 5,000 annually. Removing that barrier improves persistence among older patients, a cohort that previously abandoned therapy at high rates once they reached the coverage gap.

### Specialty and Online Home Delivery

Pharmacy benefit managers are steering biologic volume toward specialty and mail-order channels. CVS Caremark removed branded Humira from its major national formularies in April 2024 in favour of biosimilar adalimumab dispensed through its specialty arm [17]. Cold-chain shipping, nurse-led injection training, and app-based refill reminders improve adherence and convenience. These services also generate refill data that manufacturers use to monitor persistence and design patient-support programs.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Biosimilar price erosion in TNF Inhibitors | −1.3% | North America, Europe | Short-term (≤2 yr) | [15][16] |
| Prolonged diagnostic delay | −0.7% | Global | Long-term (≥4 yr) | [22] |
| Medicare negotiated pricing | −0.6% | United States | Short-term (≤2 yr) | [13] |
| Limited coverage in emerging economies | −0.6% | South America, Middle East and Africa, South Asia | Long-term (≥4 yr) | [23] |
| JAK inhibitor safety warnings | −0.5% | Global | Medium-term (2–4 yr) |   |

### Biosimilar Price Erosion in TNF Inhibitors

The FDA has approved ten adalimumab biosimilars, some of which are interchangeable. Simlandi, a high-concentration, citrate-free formulation approved in February 2024 by Teva and Alvotech, is interchangeable [15]. Global sales of Humira decreased by around a third in 2023 and even more in 2024, according to AbbVie [8]. While volume remains constant, the largest class's net revenue per patient continues to decline.

### Prolonged Diagnostic Delay

Between the onset of symptoms and diagnosis, patients usually have to wait seven to ten years [22]. Inflammatory back pain is frequently overlooked in primary care, chronic back pain is prevalent, and MRI and HLA-B27 testing are underutilized. Every year of delay results in irreparable structural damage and a year without treatment revenue, which subsequently restricts possible outcomes.

### Medicare Negotiated Pricing

CMS published negotiated prices for the first ten drugs in August 2024, including etanercept, effective January 2026 [13]. The negotiated etanercept price reflects a discount of roughly two-thirds from list price. Further negotiation rounds could capture other rheumatology biologics as they age past the statutory exclusivity threshold.

### Limited Coverage in Emerging Economies

In much of South America, Africa, and South Asia, biologics remain out-of-pocket purchases costing several times average monthly income. Prevalence is lower in these regions, at 10.2 per 10,000 in Latin America and 7.4 in Africa [23], and low diagnosis rates further shrink the addressable population.

### JAK Inhibitor Safety Warnings

The FDA required boxed warnings on JAK inhibitors in September 2021 for major cardiovascular events, malignancy, thrombosis, and death, based on the ORAL Surveillance trial. Labels now restrict use to patients with inadequate response to TNF blockers. Older patients and smokers are often steered away, capping the oral class's reach.

## Opportunities

## Ankylosing Spondylitis Treatment Market Opportunities

### Biosimilar-Led Access in Emerging Markets

Lower-cost biosimilars of adalimumab, etanercept, and infliximab can bring [biologic therapy](https://www.marketresearchfuture.com/reports/biologic-therapy-market-840) within reach of patients in India, Brazil, and the GCC for the first time. Local manufacturing partnerships and tiered pricing allow companies to trade margin for volume in populations where treatment rates remain in single digits. Companies that build rheumatologist training and diagnostic referral networks alongside supply will capture the first wave of new patients.

### Next-Generation Mechanisms for Refractory Disease

Around half of patients fail to reach ASAS40 on their first biologic, leaving a sizeable refractory pool [3]. Dual-cytokine antibodies, TYK2 inhibitors, and anti-GM-CSF candidates target this gap. Developers with head-to-head or post-TNF data can price at a premium even as the broader class commoditises.

### Real-World Data and Outcomes-Based Contracting

Specialty pharmacies, connected [autoinjectors](https://www.marketresearchfuture.com/reports/autoinjectors-market-6311), and patient apps generate persistence, dosing, and patient-reported outcome data at scale. Manufacturers can license these datasets for label-expansion studies and use them to underwrite outcomes-based contracts that refund payers when patients fail to reach BASDAI targets. This new business model shifts competition from list price to demonstrated value.

### Earlier Diagnosis Through Imaging and Referral Tools

AI-assisted reading of sacroiliac joint MRI and primary-care referral algorithms can shorten the seven-to-ten-year diagnostic gap [22]. Each year cut from that delay adds a full year of treatment revenue per patient. Manufacturers co-funding screening pathways with health systems stand to grow the treated population rather than fight over existing patients.

### Self-Injection Device Lifecycle Management

High-concentration, low-volume, citrate-free formulations reduce injection pain and dosing frequency [16]. Brands that pair these with connected autoinjectors can defend share against biosimilars that compete on price alone.

## Future Outlook

## Ankylosing Spondylitis Treatment Market Future Outlook

### AI-Assisted Imaging and Earlier Diagnosis

Machine-learning tools that flag sacroiliitis on MRI and X-ray are moving from research into clinical workflows. Shortening the average seven-to-ten-year diagnostic delay [22] would add a decade of treatment for many patients. By 2035, diagnosis rates in high-income markets could climb meaningfully, enlarging the treated population faster than prevalence alone suggests.

### Price-Reset Economics

Medicare negotiation [13], more than 60 approved biosimilars, and PBM formulary exclusions [17] are compressing prices for mature biologics. Secukinumab and ixekizumab face biosimilar competition early in the next decade. Revenue in the Ankylosing Spondylitis Treatment Market will concentrate in agents with clear differentiation, while mature molecules compete on volume and contracting.

### Oral and Multi-Target Pipelines

Oral TYK2 inhibitors, next-generation JAK agents with cleaner safety profiles, and bispecific antibodies targeting IL-17 and TNF together are in clinical development. If safety data hold, oral options could take a substantially larger share of post-TNF lines by 2035 [9].

### Home-Based Care and Digital Adherence

Self-injection, mail-order dispensing, and remote monitoring are moving care away from hospitals. The Part D cap [14] and specialty pharmacy growth [17] favour home-based models. Connected devices that record each dose will feed outcomes-based contracts and give payers evidence they currently lack.

## Segment Insights

## Ankylosing Spondylitis Treatment Market Segmentation

### By Drug Class

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| NSAIDs | 8.3% CAGR (2026–2035) | First-line guideline status and structure-modifying evidence |
| TNF Inhibitors | 50.4% share | Clinical familiarity and broad payer coverage |
| IL-17 Inhibitors | USD 1.58 Billion | Rapid entheseal relief and dual-cytokine efficacy |
| JAK Inhibitors | 7.9% CAGR (2026–2035) | Oral convenience after biologic failure |
| Biosimilars | USD 0.61 Billion | Payer-mandated switching and tender pricing |
| Others | 3.1% share | Corticosteroids, conventional DMARDs, pipeline agents |

Within the Ankylosing Spondylitis Treatment Market, TNF Inhibitors remain the backbone, with adalimumab, etanercept, infliximab, golimumab, and certolizumab pegol covering most biologic starts. IL-17 Inhibitors are the main share gainers, led by secukinumab and ixekizumab [21], with bimekizumab targeting switchers who need stronger radiographic control [10]. NSAIDs grow fastest because continuous celecoxib and etoricoxib regimens are increasingly framed as disease-modifying [11]. JAK Inhibitors serve biologic-experienced patients, while Biosimilars and Others round out a mix that is shifting toward newer mechanisms.

### By Route of Administration

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Oral | 8.5% CAGR (2026–2035) | JAK inhibitors and continuous NSAID therapy |
| Sub-cutaneous | 55.4% share | Self-administered autoinjectors and prefilled pens |
| Intravenous | USD 1.12 Billion | Infliximab and IV secukinumab for selected patients |

Subcutaneous delivery leads the Ankylosing Spondylitis Treatment Market because adalimumab, etanercept, secukinumab, ixekizumab, and bimekizumab are all self-injected at home. Oral therapy is the fastest-growing route as JAK inhibitors win post-TNF positions and payers accept tablet regimens. Intravenous use has narrowed to patients with injection-site reactions or adherence concerns, though IV secukinumab [6] has given infusion centres a new option alongside biosimilar infliximab.

### By Distribution Channel

| Segment | Key Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospital Pharmacies | 46.9% share | Biologic initiation, infusions, and safety monitoring |
| Retail Pharmacies | USD 2.14 Billion | NSAID and oral small-molecule dispensing |
| Online Pharmacies | 8.0% CAGR (2026–2035) | Cold-chain home delivery and copay support |

Hospital Pharmacies hold the largest share of the Ankylosing Spondylitis Treatment Market, handling biologic initiation, infusion services, and adverse-event management. Retail Pharmacies dispense most NSAIDs and oral agents but cede complex biologics to specialist channels. Online Pharmacies grow fastest as PBM-owned specialty arms bundle home delivery, nurse training, and refill reminders, particularly for working-age patients [17].

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| North America | 41.8% share | IL-17 and JAK uptake, biosimilar adalimumab switching, Part D affordability |
| Europe | USD 1.86 Billion | Tender-driven biosimilars, HTA-led access to newer mechanisms |
| Asia Pacific | 8.6% CAGR (2026–2035) | NRDL listing, rising diagnosis, local biosimilar production |
| Middle East and Africa | USD 0.28 Billion | GCC insurance mandates, specialist capacity building |
| South America | 5.1% share | Public procurement of biosimilars, judicial access to biologics |
| Total | USD 6.75 Billion | — |

Regional performance in the Ankylosing Spondylitis Treatment Market tracks three factors: underlying prevalence, biologic reimbursement depth, and biosimilar policy. Prevalence ranges from 31.9 per 10,000 in North America to 7.4 in Africa [23].

### North America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| United States | 86.9% of regional revenue | Broad commercial and Medicare coverage of biologics |
| Canada | USD 0.29 Billion | Provincial biosimilar switching policies |
| Mexico | 7.6% CAGR (2026–2035) | IMSS procurement and private insurance growth |

The Ankylosing Spondylitis Treatment Market in North America rests on the United States, where high prevalence, early biologic use, and premium pricing concentrate revenue. Formulary exclusions of branded Humira in 2024 accelerated biosimilar adalimumab uptake [17], while the Part D cap supports persistence among Medicare patients [14]. Canada's provinces, led by British Columbia and Ontario, mandate biosimilar transitions for public-plan patients, and Mexico's public institutes are widening biologic tenders.

### Europe

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Germany | 24.6% of regional revenue | Statutory insurance coverage and biosimilar quotas |
| United Kingdom | USD 0.33 Billion | NICE technology appraisals for IL-17 agents |
| France | 6.4% CAGR (2026–2035) | Hospital-to-community biosimilar substitution |
| Italy | 12.8% of regional revenue | Regional tenders and specialist centres |
| Spain | USD 0.17 Billion | Autonomous-community procurement |
| Rest of Europe | 5.9% CAGR (2026–2035) | Nordic tenders and Central European access gains |

European growth in the Ankylosing Spondylitis Treatment Market is moderated by aggressive biosimilar tendering that cut adalimumab prices sharply after 2018 [18]. Those savings fund access to newer agents: NICE recommended bimekizumab for [axial spondyloarthritis](https://www.marketresearchfuture.com/reports/axial-spondyloarthritis-market-37081) in 2023 after inadequate response to conventional therapy [19]. Germany remains the largest single market owing to high rheumatologist density and statutory coverage.

### Asia Pacific

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| China | 10.2% CAGR (2026–2035) | NRDL listing of IL-17 and TNF biologics |
| Japan | 31.5% of regional revenue | Early adoption of IL-17 and JAK therapies |
| India | 11.4% CAGR (2026–2035) | Domestic biosimilars and rising diagnosis |
| South Korea | USD 0.11 Billion | Biosimilar manufacturing base and NHIS coverage |
| Australia | 8.2% of regional revenue | PBS-subsidised biologic access |
| Rest of Asia Pacific | USD 0.12 Billion | Private insurance growth in Southeast Asia |

China drives Asia Pacific momentum in the Ankylosing Spondylitis Treatment Market as negotiated reimbursement lowers co-payments for biologics [20]. Japan holds the largest current revenue base through early uptake of IL-17 and JAK therapies. India's growth comes from a low base, aided by domestically produced adalimumab biosimilars priced well below originator levels. South Korea, home to Celltrion and Samsung Bioepis, combines manufacturing scale with national insurance coverage.

### Middle East and Africa

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| GCC | 46.3% of regional revenue | Mandatory health insurance in Saudi Arabia and the UAE |
| South Africa | 7.8% CAGR (2026–2035) | Private medical scheme coverage |
| Rest of Middle East and Africa | USD 0.09 Billion | Donor and government programs in select countries |

The GCC dominates regional revenue, with Saudi Arabia's health transformation program and Dubai's mandatory insurance funding biologic access. South Africa's private schemes reimburse biologics under prescribed minimum benefit rules, although public-sector access remains thin. Across much of the remaining region, low prevalence [23] and scarce rheumatology capacity limit treatment.

### South America

| Country | Key Metric (2025) | Key Driver |
| --- | --- | --- |
| Brazil | 58.7% of regional revenue | SUS public procurement and local biologic production |
| Argentina | USD 0.07 Billion | Social security coverage and biosimilar approvals |
| Rest of South America | 6.9% CAGR (2026–2035) | Colombian and Chilean reimbursement updates |

Brazil's SUS public health system purchases biologics centrally and supports technology-transfer partnerships for local production, keeping it the region's anchor. Argentina relies on social security funds and court-ordered access, which creates volatility. Currency swings across the region complicate pricing for multinational suppliers.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration in the Ankylosing Spondylitis Treatment Market is medium, with an estimated HHI of 1,350–1,600. The top five companies hold roughly 62–70% of revenue, led by owners of the major IL-17 and TNF franchises. Biosimilar entry is gradually fragmenting the TNF segment, while IL-17 and JAK classes remain concentrated among a few originators.

| Company | Est. Revenue Share Range | Key Offerings for Ankylosing Spondylitis Treatment Market | Strategic Positioning |
| --- | --- | --- | --- |
| Novartis AG | ~16–20% | Cosentyx (secukinumab) SC and IV | IL-17 leader expanding through IV formulation and new indications |
| AbbVie Inc. | ~14–18% | Humira (adalimumab), Rinvoq (upadacitinib) | Transitioning revenue from Humira to oral Rinvoq |
| Amgen Inc. | ~8–11% | Enbrel (etanercept, U.S.), Amjevita | Defending etanercept post-negotiation; biosimilar adalimumab supplier |
| Johnson & Johnson | ~7–10% | Simponi, Simponi Aria, Remicade | Mature TNF portfolio with IV option |
| UCB S.A. | ~6–9% | Bimzelx (bimekizumab), Cimzia | Dual IL-17A/F differentiation for switchers |
| Pfizer Inc. | ~6–9% | Enbrel (ex-U.S.), Xeljanz, Inflectra | Oral JAK plus infliximab biosimilar |
| Eli Lilly and Company | ~5–8% | Taltz (ixekizumab) | IL-17A challenger in radiographic and non-radiographic disease |
| Celltrion Inc. | ~2–4% | Remsima (IV/SC), Yuflyma | Biosimilar leader with SC infliximab outside the U.S. |
| Sandoz Group AG | ~2–4% | Hyrimoz, Erelzi | Scale biosimilar supplier after Novartis spin-off |
| Samsung Bioepis | ~1–3% | Hadlima, Benepali, Flixabi | Partnered biosimilar portfolio across TNF molecules |
| Merck & Co., Inc. | ~1–3% | Remicade and Simponi (select ex-U.S. markets) | Regional commercialiser of TNF brands |

## Recent News & Developments

## Recent News & Developments

- Celltrion (May 2023): The FDA approved Yuflyma, a high-concentration, citrate-free adalimumab biosimilar, intensifying price competition in TNF Inhibitors [16]
- Novartis (October 2023): The FDA approved an intravenous Cosentyx formulation for AS, nr-axSpA, and psoriatic arthritis, giving IL-17 blockade access to infusion settings [6]
- Teva and Alvotech (February 2024): Simlandi gained FDA approval as an interchangeable high-concentration adalimumab biosimilar, easing pharmacy-level substitution [15]
- CVS Caremark (April 2024): Branded Humira was removed from major national formularies in favour of biosimilars, shifting volume toward specialty channels [17]
- CMS (August 2024): Negotiated Medicare prices were published for ten drugs, including etanercept, effective January 2026 [13]
- UCB (September 2024): The FDA approved Bimzelx for radiographic and non-radiographic axial disease, adding a dual IL-17A/F option [5]
- CMS (January 2025): The USD 2,000 Part D out-of-pocket cap took effect, lowering financial barriers for Medicare patients on biologics [14]

## Report Scope

| Parameter | Details |
| --- | --- |
| Market Scope | Prescription therapies for ankylosing spondylitis, including NSAIDs, TNF, IL-17 and JAK inhibitors, biosimilars and other agents, delivered orally, subcutaneously or intravenously through hospital, retail and online pharmacies |
| Study Period | 2021–2035 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2035 |
| Market Size in 2025 | USD 6.75 Billion |
| Market Size in 2035 | USD 13.13 Billion |
| CAGR (2026–2035) | 6.9% |
| Fastest Growing Segments | NSAIDs (8.3% CAGR); Oral (8.5% CAGR); Online Pharmacies (8.0% CAGR); JAK Inhibitors (7.9% CAGR) |
| Regions Covered | North America, Europe, South America, Asia Pacific, Middle East and Africa and ROW |
| Companies Profiled | Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, UCB S.A., Pfizer Inc., Eli Lilly and Company, Celltrion Inc., Sandoz Group AG, Samsung Bioepis, Merck & Co., Inc. |
| Valuation Currency | USD Billion |
| Methodology | 350+ primary expert interviews; bottom-up market sizing; top-down validation; data triangulation; scenario-based forecasting; real-time project tracking |

## Frequently Asked Questions

**Q: How do biosimilar interchangeability designations affect the Ankylosing Spondylitis Treatment Market?**
A: Interchangeable status lets U.S. pharmacists substitute a biosimilar without prescriber approval, subject to state law. In the Ankylosing Spondylitis Treatment Market, this speeds adalimumab switching and weakens originator rebate leverage [15].

**Q: Which clinical endpoint matters most when payers compare therapies in the Ankylosing Spondylitis Treatment Market?**
A: ASAS40 response at week 12–16 is the primary comparator in most formulary reviews. Payers in the Ankylosing Spondylitis Treatment Market increasingly also request ASDAS-based data because it combines symptoms with CRP levels [3].

**Q: What should new entrants consider before launching in the Ankylosing Spondylitis Treatment Market?**
A: Entrants need head-to-head or post-TNF data because payers rarely reimburse a fourth undifferentiated mechanism. Partnering with specialty pharmacies early secures distribution and patient-support infrastructure [17].

**Q: How does HLA-B27 testing influence treatment demand?**
A: About 90% of patients of European ancestry carry HLA-B27, making it a key screening aid [1]. Wider use of the test in primary care increases rheumatology referrals and earlier biologic eligibility.

**Q: Are anti-IL-23 drugs effective in ankylosing spondylitis?**
A: Ustekinumab and risankizumab failed to show benefit in axial disease trials, despite working in psoriatic arthritis [3]. This failure keeps IL-17 and TNF agents dominant in spinal disease.

**Q: How does pregnancy planning shape drug selection?**
A: Certolizumab pegol shows minimal placental transfer, so many rheumatologists prefer it for women planning pregnancy [2]. JAK inhibitors are generally avoided during pregnancy.

**Q: What role does physiotherapy play alongside pharmacological treatment?**
A: Guidelines recommend supervised exercise for every patient, regardless of drug therapy [2][3]. Combined exercise and medication improves spinal mobility and function more than drugs alone.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/ankylosing-spondylitis-treatment-market-12171*
